Some cancer cells survive as senescent cells through the DNA damage response after chemotherapy. 5 Senescence is a state in which cells undergo irreversible cell cycle arrest in response to various stresses. 6 Senescence is induced not only in normal cells but also in cancer cells when anticancer agents trigger DNA damage. 7, 8 Recent studies have indicated that senescent cells show growth arrest and increased secretion of secretory proteins, including inflammatory cytokines, chemokines, growth factors, and MMPs, which is designated as the senescence-associated secretory phenotype (SASP). 9 Although growth arrest in senescent cancer cells has a tumor suppressive effect, their SASP features are reported to contribute to tumor promotion and recurrence. 10 Immune checkpoint blockade (ICB) Ab therapy has attracted attention as a promising anticancer therapy against some types of cancer. 11 To increase its therapeutic efficacy, ICB Ab therapy must be combined with other types of treatment, including chemotherapy and/or radiotherapy. 12, 13 Alternatively, chemotherapy has been shown to modulate immune responses both positively and negatively. Chemotherapeutic drugs exert several immune-enhancing effects, including relief of immune suppressor cells 14, 15 and the induction of immunogenic cancer cell death. 16 Conversely, they induce immunosuppressive conditions, such as immune suppression when administered at higher doses, subsequent recruitment of immune suppressor cells, 17 and the induction of immune checkpoint molecules on cancer cells. 18 Clinically, the combination of ICB Ab therapy with chemotherapy has been reported to show therapeutic efficacy. 12, 13 However, the mutual effects of anticancer immunotherapy We also examined the sensitivity of cancer cells treated with either DXR or the cyclin-dependent kinase (CDK)4/6 inhibitor abemaciclib, which induces senescence.
| MATERIAL S AND ME THODS

| Cell lines and reagents
Three human breast cancer cell lines, MDA-MB-231, BT-549, and MCF-7
(kindly provided by Dr. K. Takenaga, Faculty of Medicine, Shimane University, Izumo, Japan), were maintained in DMEM (Sigma-Aldrich)
supplemented with 10% FCS (Invitrogen) and 20 μg/mL gentamicin (Sigma-Aldrich) at 37°C in a humidified atmosphere of 5% CO 2 in air.
Doxorubicin (Sigma-Aldrich) was diluted first in distilled water and subsequently in PBS. Anti-tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) Ab was purchased from BioLegend. Concanamycin A (CMA) was purchased from Santa Cruz Biotechnology. Recombinant TRAIL was purchased from PeproTech. Anti-CD3 Ab (clone UCHT1) was purchased from Ancell.
| Preparation of effector immune cells
Anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR)-T cells were purchased from ProMab. After initial thawing, these cells were cultured in RPMI-1640 supplemented with 2% human serum and 300 U/mL interleukin (IL)-2 for 10 days. The cultured cells were aliquoted in vials and kept at −70°C. For each experiment, these T cells were expanded in anti-CD3 Ab-coated plates with 300 U/mL IL-2 for 7-10 days.
| Cell viability assay
Cell viability was measured using the 2-(2-methoxy-4-nitrophe-
osodium salt (WST-8) assay (Nacalai Tesque). Briefly, cells were seeded in flat-bottomed 96-well plates and DXR was added at the indicated doses. Two days later, 10 μL WST-8 solution was added to each well after removal of half of the medium, and the plates were incubated for an additional 3 hours. The plates were then read at a wavelength of 450 nm using a microplate reader (Beckman Coulter).
| Flow cytometric analysis
Apoptosis was measured using an annexin V- 
| Preparation of human NK cells and Abdependent cell-mediated cytotoxicity assay
Natural killer cells were prepared from peripheral blood of healthy donors. Peripheral blood mononuclear cells were prepared from blood using Lymphocyte Separation Solution (Nacalai Tesque).
Natural killer cells were enriched using an NK Cell Purification 20140918-2).
| Detection of senescence-associated β-Gal
Senescence-associated β-galactosidase (SA β-Gal) was detected by flow cytometry and confocal imaging. Confocal imaging was carried out using a laser scanning microscope (FV1000-D; Olympus).
| Assay of cytotoxicity with flow cytometry
To examine apoptotic cancer cells, they were cocultured with acti- 
| Immunoblotting assay
Cancer cells were lysed with RIPA Buffer (Fujifilm Wako Pure Chemical) containing a protease inhibitor cocktail (Nacalai Tesque) and a phosphatase inhibitor cocktail (Nacalai Tesque). Equal amounts of protein were resolved on 4%-12% gradient or 12% SDS-PAGE gels, followed by transfer onto PVDF membranes. After blocking the membranes, the blots were incubated with the indicated primary Abs: anti-p21 Cip1/Waf1 (#2947; Cell Signaling Technology), anti- 
| Enzyme-linked immunosorbent assay
The levels of human IL-6 and IL-8 in the supernatants were determined using an ELISA kit (PeproTech). The levels of soluble TRAIL in the supernatants of activated T cells were determined using an ELISA kit (PeproTech).
| Statistical analysis
Data were statistically evaluated using the unpaired 2-tailed Student's t test. In all analyses, P < .05 was taken to indicate statistical significance.
| RE SULTS
| Doxorubicin induces senescence in MDA-MB-231 and BT-549 cells
We first examined the effects of DXR on 3 human breast cancer 
| Increased sensitivity of DXR-treated MDA-MB-231 and BT-549 cells to T cells
We next examined whether DXR-induced senescence could influence the sensitivity of breast cancer cells to immune cell-mediated cytotoxicity. We attempted to utilize anti-EGFR CAR-T cells as ef- 
| Perforin is involved in enhanced sensitivity of DXR-treated cancer cells to ADCC by NK cells and anti-HER2 Ab
We next examined the sensitivity of DXR-treated MDA-MB-231 cells to ADCC induced by NK cells and anti-HER2 Ab. The (Figures 4C and S4A) . In (Figures 4D and S4B ).
| Different sensitivities of senescent cancer cells induced by DXR or abemaciclib to cytotoxicity
We finally examined whether the senescent phenotype is needed for the increased sensitivity to cell-mediated cytotoxicity. We utilized the CDK4/6 inhibitor abemaciclib as a senescence inducer. 22, 23 Abemaciclib treatment increased cell size as well as the expression of SA β-Gal in MDA-MB-231 cells ( Figure 5A ), but decreased their expression of EGFR ( Figure 5B ). In addition, abemaciclib treatment increased the sensitivity of cancer cells to T cells (Group 2 vs Group 6), whereas the enhancement was apparently lower than that of DXR
treatment (Group 2 vs Group 4) (Figures 5C and S5). Similar results
were observed in terms of sensitivity to ADCC by NK cells and anti-EGFR Ab (Group 8 vs Group 9). We also examined the expression of antiapoptotic proteins and found that, in contrast to the decreased expression of cFLIP and Mcl-1 in DXR-treated MDA-MB-231 cells ( Figure 3D ), abemaciclib treatment showed no definite effect on the expression of these proteins ( Figure 5D ). In addition, the expression of γH2AX was not detected in abemaciclib-treated MDA-MB-231 cells ( Figure 5E ).
| D ISCUSS I ON
A major mechanism underlying the anticancer effects of chemotherapeutic drugs is the induction of DNA damage. In this study, After harvesting, cancer cells were cultured with prepared NK cells with the indicated Ab for 6 h. After harvesting these cells, whole cells were first stained with anti-CD45-APC, followed by annexin V-FITC and analyzed by flow cytometry, as Figure 2B . Results of 3 wells are shown. *P < .05, **P < .01, ***P < .005. D, Similarly, DXR-treated MDA-MB-231 cells were cultured with prepared NK cells with the indicated Ab for 6 h. In some groups, either anti-TRAIL Ab, control mouse IgG, concanamycin A (CMA), or DMSO as a vehicle control was added 1 h before the addition of cancer cells. After harvesting these cells, whole cells were first stained with anti-CD45-APC, followed by annexin V-FITC and analyzed by flow cytometry, as Figure 2B . Results of 3 wells are shown. **P < .01, ***P < .005
we showed that DXR induced the expression of γH2AX and typical senescence in MDA-MB-231 and BT-549 cells, but not in MCF-7 cells. One possible explanation why γH2AX was not detected and SASP was not induced in DXR-treated MCF-7 cells is that MDA-MB-231 and BT-549 cells carry mutant p53, but MCF-7 cells have WT p53. 24 The tumor suppressor p53 acts to restrict proliferation in response to DNA damage or deregulation of mitogenic oncogenes, leading to apoptosis or cellular senescence. 25 In general, growth arrest is achieved and maintained in either the G 1 or G 2 /M phase of the cell cycle, in part by the increased expression of specific CDK inhibitors, including p16 ink4A and p21 Waf1 . 26 Senescence growth arrest is largely induced by either or both of the p53/ p21 Waf1 and p16 ink4A /pRb tumor suppressive pathways; p21
Waf1 is a downstream effector of p53, whereas p16 ink4A is a positive upstream regulator of pRb. 6 Doxorubicin treatment increased p21 expression in MCF-7 cells, probably through p53 activation, whereas no change was observed in γH2AX expression. We assumed that cell death of DXR-treated MCF-7 cells occurred too rapidly to detect γH2AX expression. In addition, it has been reported that SASP is limited by WT p53. 27 Therefore, MCF-7 cells were limited in their acquisition of the SASP features due to WT p53, whereas p53-mutated MDA-MB-231 and BT-549 cells showed a strong SASP response.
As for the reason why the level of SA β-Gal expression in DXRtreated MCF-7 cells was low, we propose that this observation was due to their inability to produce IL-6 and IL-8, as reported previously. 28 Indeed, we observed no production of these cytokines by untreated and DXR-treated MCF-7 cells. Doxorubicin induced senescence-like changes in MCF-7 cells, while they lacked SASP.
Interestingly, treatment of MCF-7 cells with IL-6 and/or IL-8 can induce senescence, leading to tumor aggressiveness. 29 Interleukin-6 and IL-8 are known to be responsible for the maintenance and propagation of the SASP response in the tumor microenvironment 9, 27 and regulation of the inflammatory phenotype. 30, 31 Clinically, elevated serum levels of IL-6 and IL-8 have been used independently as prognostic markers for breast cancer, 32 and both cytokines are essential for cell growth in TNBC cells. 33 These cytokines are likely to play crucial roles in the pathogenesis of breast cancer.
In this study, we examined the sensitivity of DXR-induced Cyclin-dependent kinase 4/6 inhibitors have attracted a great deal of attention as a promising therapy for breast cancer. 22 The effectiveness of palbociclib has been reported in phase III clinical trials in estrogen receptor-positive breast cancers. 36 In addition, CDK4/6
inhibitors are known to induce senescence. 22, 23 The most notable finding in this study was that senescent MDA-MB-231 cells showed increased sensitivity to cytotoxicity only after DXR treatment. This difference seemed to be due to their effects on the expression of the antiapoptotic proteins cFLIP and Mcl-1. In addition, DXR induced long-term growth arrest, whereas abemaciclib-treated cancer cells regrew after the removal of this agent. These results could have been due to the fact that DXR induces senescence through DNA damage, whereas abemaciclib induces senescence by inhibiting CDK4/6 function without DNA damage.
Several reports have suggested that CDK4/6 inhibitors can enhance antitumor immunity in vivo. Two studies showed that CDK4/6 inhibitors, including abemaciclib, triggered antitumor immunity through T cell activation in murine tumor models. 37, 38 Similarly, abemaciclib has been reported to upregulate antigen presentation by cancer cells and increase T cell activation. 39 In these preclinical studies, the combination with PD-1/PD-L1 blockade further enhanced the antitumor effects. Although we focused on the in vitro effects of DXR and abemaciclib on human breast cancer cells in this study, CDK4/6 inhibitors have the potential to enhance the therapeutic efficacy in combination with anticancer immunotherapy. 40 In conclusion, the results of the present study indicated that both DXR and the CDK4/6 inhibitor abemaciclib induce senescence in breast cancer cells, but that they show contrasting sensitivity to immune cell-mediated cytotoxicity. Given that senescent cells with SASP induce tumor promotion and recurrence, 9,10 targeting senescent cancer cells and noncancer cells could be a promising strategy to increase the efficacy of treatment and to control tumor recurrence.
In addition, our results provide a possible strategy for combining anticancer immunotherapy with DNA damage-inducing chemotherapeutic drugs or function-blocking molecular targeting drugs.
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